Data DEA Policy Therapy 
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
DECEMBER 27, 2022
Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct. The subjective nature of self-reported data can plague research. Always consult a physician before attempting alternative therapies.
CannaMD
SEPTEMBER 10, 2020
Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.
Cannabis Law Report
AUGUST 23, 2021
He added that significant data is still needed to inform policy regarding use of consumer cannabis products. She acknowledged that “FDA is considering the possibility of new legal pathways for CBD products.”. As a matter of a First Amendment right to free speech, vets should be able to talk to pet owners about CBD.
Canna Law Blog
NOVEMBER 6, 2021
But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). The first is legislative.
Cannabis Law Report
APRIL 8, 2022
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,
Expert insights. Personalized for you.
98 
Let's personalize your content